Altria Group Inc MO has raised its adjusted diluted EPS guidance for 2016, implying 7.5–9.6 percent growth from the 2015 levels.
Argus’ David Coleman maintains a Buy rating on the company, while raising the price target from $71 to $73.
The Positives
“The company has a strong balance sheet and pays a solid dividend with a yield of about 3.3 percent. It also has a range of top-selling brands, such as Marlboro & Parliament, that are able to command premium pricing, as well as less expensive brands that are less vulnerable to rising cigarette taxes,” Coleman mentioned.
The analyst also noted that Altria Group has lowered its exposure to the tobacco industry risks by expanding into non-tobacco businesses.
New Regulations
Coleman expects the company to benefit from the new regulations regarding the sale of e-cigarettes and vaporizers, given that higher safety costs have a larger impact on smaller manufacturers, who at present hold a large share of the smokeless market.
“Although the new regulations will not take effect for several years, they should benefit Altria and other large producers that have the resources to manage the FDA approval process. By pressuring smaller manufacturers, they could also be a catalyst for industry consolidation,” the analyst stated.
2Q Results
Altria Group reported its 2Q results on July 27, with the EPS beating the estimate and the consensus and the revenue net of excise taxes coming in flat with the year-ago quarter, although missing the consensus.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.